IDEAYA Biosciences Inc IDYA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:11 AM EDT
41.19quote price arrow up+0.02 (+0.05%)
Volume
33,857
52 week range
20.84 - 47.74
Loading...
  • Open41.45
  • Day High41.61
  • Day Low41.02
  • Prev Close41.17
  • 52 Week High47.74
  • 52 Week High Date02/15/24
  • 52 Week Low20.84
  • 52 Week Low Date05/18/23

Key Stats

  • Market Cap3.118B
  • Shares Out75.69M
  • 10 Day Average Volume0.61M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change15.6

KEY STATS

  • Open41.45
  • Day High41.61
  • Day Low41.02
  • Prev Close41.17
  • 52 Week High47.74
  • 52 Week High Date02/15/24
  • 52 Week Low20.84
  • 52 Week Low Date05/18/23
  • Market Cap3.118B
  • Shares Out75.69M
  • 10 Day Average Volume0.61M
  • Dividend-
  • Dividend Yield-
  • Beta0.81
  • YTD % Change15.6

RATIOS/PROFITABILITY

  • EPS (TTM)-2.00
  • P/E (TTM)-20.59
  • Fwd P/E (NTM)-18.24
  • EBITDA (TTM)-156.594M
  • ROE (TTM)-20.31%
  • Revenue (TTM)15.504M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-831.35%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On IDEAYA Biosciences Inc

 

Profile

MORE
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine...
Terry Rosen Ph.D.
Independent Chairman of the Board
Yujiro Hata
President, Chief Executive Officer, Director
Address
7000 Shoreline Ct Ste 350
South San Francisco, CA
94080-7604
United States

Top Peers

SYMBOLLASTCHG%CHG
XENE
Xenon Pharmaceuticals Inc
41.38+0.84+2.06%
JANX
Janux Therapeutics Inc
49.15+0.23+0.47%
SWTX
SpringWorks Therapeutics Inc
41.57+0.68+1.66%
ARWR
Arrowhead Pharmaceuticals Inc
21.99-0.09-0.41%
MLTX
MoonLake Immunotherapeutics
42.20+1.27+3.12%